ELV
Elevance Health, Inc.351.90
-8.77-2.43%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
79.24BP/E (TTM)
14.35Basic EPS (TTM)
24.53Dividend Yield
0.02%Recent Filings
8-K
8-K
10-Q
Q3 FY2025 results
Elevance Health posted solid Q3 results, with operating revenue climbing 12.0% year-over-year to $50.1B, fueled by premium rate hikes across Health Benefits and Medicare Advantage membership growth, though Medicaid attrition tempered gains. Premiums surged 13.5% y/y to $41.8B, while the benefit ratio edged up to 91.3% from 89.5% amid elevated Medicare and commercial trends; operating income dipped 8.0% y/y to $1.3B, but diluted EPS jumped 22.0% to $5.32 on fewer shares and lighter tax hits. YTD, revenue rose 13.9% to $148.3B with EPS at $22.67, down 4.8% y/y, reflecting Health Benefits pressures offset by CarelonRx and Services gains. Cash swelled to $8.7B, bolstered by $4.2B operating flow, while total debt hit $31.9B after fresh notes issuance; free cash flow stood at $3.4B (derived). December 2024's CareBridge buy added $1.8B goodwill and $305M intangibles (amortized over undisclosed lives), enhancing home-based Medicaid care. Solid balance sheet shines. Yet antitrust suits linger as a key risk.
8-K
Q3 revenue up 12%, costs rise
Elevance Health posted third-quarter 2025 operating revenue of $50.1 billion, up 12% from last year, fueled by premium growth and acquisitions, yet adjusted operating gain dipped to $1.3 billion amid Medicare cost pressures from Inflation Reduction Act changes. Benefit expense ratio climbed to 91.3%, while membership held at 45.4 million despite Medicaid losses. Revenue surged. The company reaffirmed its full-year adjusted EPS guidance at $30.00, underscoring steady capital returns of $3.3 billion year-to-date.
8-K
Elevance Health closes $3B notes
Elevance Health closed a $3 billion notes offering on September 15, 2025, issuing $750 million of 4.000% notes due 2028, $750 million of 4.600% notes due 2032, $1 billion of 5.000% notes due 2036, and $500 million of 5.700% notes due 2055. Net proceeds of $2,972.7 million will repay $400 million 5.350% notes due 2025 and $500 million 4.900% notes due 2026, with the rest for working capital, acquisitions, debt repayment, and stock repurchases. This refinancing extends maturities while locking in lower rates. Redemption options add flexibility, but change-of-control triggers a 101% buyback.
IPO
Employees
Sector
Industry
CI
The Cigna Group
276.11-1.04
CLOV
Clover Health Investments, Corp
2.64+0.02
CNC
Centene Corporation
38.97-1.48
CTEV
Claritev Corporation
38.35+0.39
CVS
CVS Health Corporation
78.29-1.40
EHTH
eHealth, Inc.
4.28-0.03
EVH
Evolent Health, Inc
4.07-0.05
HUM
Humana Inc.
258.16-16.58
NEUE
NeueHealth, Inc.
6.75+0.00
UNH
UnitedHealth Group Incorporated
334.20-6.90